Mast cells have been invoked as important players in immune responses associated with autoimmune diseases. Based on in vitro studies, or in vivo through the use of Kit mutant mice, mast cells have been suggested to play immunological roles in direct antigen presentation to both CD4 + and CD8 + T cells, in the regulation of T and dendritic cell migration to lymph nodes, and in Th1 versus Th2 polarization; all of which could significantly impact the immune response against self antigens in autoimmune disease, including type 1 diabetes (T1D). Until now, the role of mast cells in the onset and incidence of T1D has only been indirectly tested through the use of low-specificity mast cell inhibitors and activators, and published studies reported contrasting results. Our three laboratories have generated independently two strains of mast cell-deficient NOD mice, NOD.Cpa3 Cre/+ (Heidelberg), and NOD.Kit W-sh/W-sh (Leuven and Boston), to address the effects of mast cell deficiency on the development of T1D in the NOD strain. Our collective data demonstrate that both incidence and progression of T1D in NOD mice are independent of mast cells. Moreover, analysis of pancreatic lymph node cells indicated that lack of mast cells has no discernible effect on the autoimmune response, which involves both innate and adaptive immune components. Our results demonstrate that mast cells are not involved in T1D in the NOD strain, making their role in this process nonessential and excluding them as potential therapeutic targets.
ABSTRACT

Mast cells have been invoked as important players in immune responses associated with
autoimmune diseases. Based on in vitro studies, or in vivo through the use of Kit mutant mice, mast cells have been suggested to play immunological roles in direct antigen presentation to both CD4 + and CD8 + T cells, in the regulation of T and dendritic cell migration to lymph nodes, and in Th1 versus Th2 polarization; all of which could significantly impact the immune response against self antigens in autoimmune disease, including type 1 diabetes (T1D). Until now, the role of mast cells in the onset and incidence of T1D has only been indirectly tested through the use of low-specificity mast cell inhibitors and activators, and published studies reported contrasting results. Our three laboratories have generated independently two strains of mast cell-deficient NOD mice, NOD.Cpa3 Cre/+ (Heidelberg), and NOD.Kit W-sh/W-sh (Leuven and Boston), to address the effects of mast cell deficiency on the development of T1D in the NOD strain. Our collective data demonstrate that both incidence and progression of T1D in NOD mice are independent of mast cells. Moreover, analysis of pancreatic lymph node cells indicated that lack of mast cells has no discernible effect on the autoimmune response, which involves both innate and adaptive immune components. Our results demonstrate that mast cells are not involved in T1D in the NOD strain, making their role in this process nonessential and excluding them as potential therapeutic targets.
INTRODUCTION
Mast cells are innate immune cells that are the main effectors in IgE-mediated allergic inflammation. In response to cross-linking of the high affinity IgE receptor FcεRI, mast cells release preformed molecules stored in granules, such as histamine, proteoglycans and proteases that can contribute to allergic inflammation and to anaphylactic shock (1) .
In addition to this well-established role in IgE-mediated allergic diseases, mast cells, due to the plethora of factors that they can produce, are believed to take part in, and modulate, many immune responses, including autoimmunity. Based on either correlative evidence, for instance the presence of mast cells in inflamed tissues, or through the use of mast celldeficient Kit mutant mice and mast cell-inhibitors, mast cells have been suggested to play roles in several autoimmune diseases that include thyroid eye disease (2), bullous pemphigoid (3), pemphigus vulgaris (4), rheumatoid arthritis (5), multiple sclerosis (6), systemic sclerosis (7, 8) , Guillain-Barre syndrome (9) and, notably, type 1 diabetes (T1D) (10-13) (reviewed in (14, 15) . However, recent experiments in newly developed Kitindependent mast cell-deficient mice did not corroborate the proposed roles for mast cells, at least in models of rheumatoid arthritis and multiple sclerosis (16) . The observed discrepancies call for a re-evaluation of mast cell functions in models more specific than the traditional Kit mutants (reviewed in (17, 18) ).
T1D, which affects approximately 37 of every 100,000 children ages 14 or younger in countries with the highest incidence (19) , results from an autoimmune attack on insulin-producing β cells by both cellular and humoral components of the immune system. In humans, the susceptibility for T1D is linked to the histocompatibility leukocyte antigen (HLA) locus (20) . Akin to humans, in the universally utilized non-obese diabetic (NOD) mouse model of T1D, the highest genetic contributor to disease susceptibility maps to the major histocompatibility complex (21, 22) . In view of the T cell-dependency of this disease, and the putative roles of mast cells in the control of T cell responses, which may occur via direct antigen presentation to either CD4 + or CD8 + T cells (23) (24) (25) , by induction of T cell migration to lymph nodes (26, 27) , by control of dendritic cell activation and migration to lymph nodes (28) (29) (30) (31) , or by control of the Th1 versus Th2 skewing (32) (33) (34) (35) , it has been postulated that mast cells are likely important players in the development of T1D (14, 15, 36 Statistical analyses. Progression to diabetes and diabetes incidence were calculated using the product limit method (Kaplan Meier analysis). Statistical significance between a pair of curves was determined by the log-rank (Mantel-Cox) test using Prism 5.0 software. Flow cytometry data were analyzed with two-tailed student t test. P values ≤ 0.05 were considered statistically significant.
RESULTS
Analysis of mast cells in pancreas and pancreatic lymph nodes in normal and mast cell-deficient NOD mice
As mast cell deficient models, we used Cpa3 Cre/+ mice which lack mast cells and are Fig. 2 ). To substantiate the mast cell-deficient phenotype by histological analysis, paraffin-embedded ear sections were stained with toluidine blue; these showed a large number of mast cells delineating the epidermis (larger magnification image depicts mast cells) in the NOD.Cpa3 +/+ mice (Fig. 1C-D) and complete absence of mast cells in the sections of NOD.Cpa3 Cre/+ mice (Fig. 1E) .
Flow cytometric analysis of pancreatic lymph node cells showed the presence of mast cells in NOD.Cpa3 +/+ mice supporting previous reports (Fig. 1F) (10, 13) . However, these cells were absent in NOD.Cpa3 Cre/+ mice (Fig. 1G) . Moreover, flow cytometric analysis of peritoneal lavage cells revealed that approximately 4% of all CD45 + cells in the peritoneal cavity of NOD.Cpa3 +/+ mice were mast cells (Fig. 1H) , while mast cells in the peritoneal cavity lavage of NOD.Cpa3 Cre/+ mice were undetectable (Fig. 1I) . Fig. 2A) . A parallel study was conducted for a cohort of male mice and again no differences were found between NOD.Cpa3 Cre/+ , NOD.Cpa3 +/+ and NOD/ShiLtJ mice (Fig. 2B ).
Comparing male and female mice, the sex differences (44) 
Insulitis assessment
Histological analyses were performed on serial paraffin sections of pancreata stained by Based on these pancreas tissue samples numbers of islets per mouse did not differ between genotypes (Supplementary Fig. 1F ). Quantification of insulitis showed no differences in scores comparing female (Fig. 3A) and male (Fig. 3B) Fig. 4 ).
In summary, these experiments establish that the incidence, progression and histopathological degree of insulitis during diabetes development are unaffected by the presence or absence of mast cells in the NOD mouse. and NOD.Cpa3 Cre/+ (n = 9) mice, we determined in the PLN the relative proportions of T cells, B cells, and dendritic cells (Fig. 4A-C) , all of which were similar in both genotypes. In accordance to earlier analysis (16) , proportions of CD4 + (Fig. 4D ) and CD8 + (Fig. 4E ) cells among total T cells, and the fraction of T regulatory cells per total CD4 + T cells (Fig. 4F ) were all not affected by mast cell deficiency.
Analysis of the immune cell populations and T cell activation in mast cell
Immune-driven effector cell differentiation of conventional T cells was assessed by expression analysis for CD62L and CD44, and T cells were classified into three categories: naïve cells (CD62L + CD44 -), central memory cells (CD62L + CD44 + ) and effector memory cells (CD44 + CD62L -) (reviewed in (45) . In the CD4 T cell population (Fig. 4G) , percentages of naïve, central memory and effector memory subsets were comparable in NOD.Cpa3 Cre/+ mice and NOD.Cpa3 +/+ mice.
Collectively, all analyzed immunological parameters were similar comparing mast cell-deficient and mast cell-proficient NOD mice. This is in full agreement with the lack of evidence for a role of mast cells on incidence, progression or degree of insulitis during diabetes development in the NOD strain.
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DISCUSSION
Many years of work by several groups leading to the current study have postulated that mast cells are important players in the initiation and progression of autoimmune diseases (14, 15, 36, 46, 47) . In most cases, these studies have been performed using non-specific mast cell "stabilizers" (48) , or Kit mutant mice that, although mast cell-deficient, have other immune (18) and relevant non-immune abnormalities, which include, notably the recent discovery of the role of Kit in pancreatic β cell function (49) . Taking into account the pleiotropic abnormalities in Kit mutant mice it is conceivable that several roles that have been attributed to mast cells are not mast cell-specific, but instead caused by the Kit mutations. To circumvent this problem, our group (16) and others (50, 51) have generated
Kit-independent mast cell-deficient mice; experiments in these mice have already challenged the role of mast cells in antibody-induced autoimmune arthritis and experimental autoimmune encephalomyelitis (16) . The role of mast cells in the autoimmune destruction of β cells, or T1D, is not well understood. In fact, although highly speculated (14, 15, 36) , the effect of mast cell deficiency on T1D had never been directly assessed genetically in vivo, with the exception of an abstract suggesting that NOD.Kit W/Wv mice failed to develop type 1 diabetes (Julianne Hatfield, Mary Quirion, Kavitha Rao, and Melissa Brown. J Immunol 184:135.39; 2010). Indirectly, one study tested the effect of mast cell inhibition using the mast cell-stabilizer DSCG, and found that this significantly delayed the onset of T1D (10); however, the specificity and function of this drug is controversial (48) . In contrast, a second study activated mast cells and basophils via anti-FcεR1 antibody treatment, and reported that this treatment delayed the onset of T1D (11) . It is difficult to interpret these opposing results, and therefore the role of mast cells on T1D remained at best controversial.
In the present study, we assessed the potential effects of mast cell deficiency on T1D, using both a traditional Kit mutant (Kit W-sh/W-sh ) and the more recent Kitindependent mast cell-deficient Cpa3 Cre/+ strain. Both strains were backcrossed to the NOD background until the new lines developed diabetes with similar onset times and rates as the NOD/ShiLtJ mice housed under identical conditions. We present data from independent studies conducted in three different institutions, all of which showed that lack of mast cells did not affect the incidence and progression of T1D in mast cell Collectively, at least two certain conclusions can be drawn from this study: firstly, the T1D autoimmune response in NOD mice is mast cell-independent, as well as independent from defects associated with hypomorphic mutations in Kit. Secondly, our study, along with earlier studies (16) , put into question the suggested ability of mast cells to control or modulate autoimmunity-promoting adaptive immune response (14, 46) .
Mast cell deficiency did not affect the levels of conventional or regulatory T cells, B cells, or dendritic cells in the pancreatic lymph nodes; moreover, T cell activation, much of which had previously been suggested to be associated with mast cell function, was also unaffected by mast cell deficiency (23) (24) (25) (28) (29) (30) (31) (32) (33) (34) (35) . Obviously, we refrain from extrapolating negative data obtained in experiments on arthritis, EAE (16) , and T1D (this study) to the potential roles of mast cells in other autoimmune responses, or adaptive immunity in general. However, as discussed recently (17, 52) , it remains important to reevaluate mast cell functions, which had previously been suggested based on in vitro experiments, on the use of inhibitors or mast cell stabilizers, or on the use of Kit mutants, by turning to more conclusive in vivo mouse models for mast cell deficiency.
Although our results clearly show that mast cell deficiency does not affect T1D development in NOD mice, our results suggest, but do not prove, that mast cells are unimportant in rat and human T1D. In the BioBreeding (BB) DR lyp/lyp rat, upregulation of mast cell genes in the pancreatic lymph nodes suggest that mast cell numbers or their activity increase during the disease (13) , and in this model disease onset was delayed by mast cell-stabilization (10) . A link between T1D progression and mast cell activation has also more generally been invoked in parasite infections or during asthma which might be negatively correlated to T1D development (11, 36, 53) . Further experiments should test these ideas by examining the prevalence of T1D in patients with mastocytosis or by studying the dependency on mast cells of helminth-mediated T1D inhibition. As it stands, mast cells are likely to play important evolutionarily conserved roles in immunity beyond their notorious role in allergic diseases. While beneficial mast cells roles are emerging in venom degradation (54, 55) , and in IgE-mediated protection from lethal doses of venom (56, 57) , the possible involvement of mast cells in the regulation of innate and adaptive immune responses, and their role as effector cells remains enigmatic.
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